Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicenter trial.

Fiche publication

Date publication

février 2021

Journal

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Pr LEPAGE Côme , Dr ROMAIN Benoit

Tous les auteurs :
Karoui M, Gallois C, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33580623

Résumé

Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. We report the 3-year oncological outcomes of the PRODIGE 22 trial.